Ye Chen

Ye Chen

Auto-generated profile, based on publicly available information

Ye Chen

Department of Neurosurgery and Pediatric Cancer Research Center, Children’s Hospital Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents’ Health and Diseases , Hangzhou

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2020 in Oncogene
Verified
Journal Article
Open access
PDF file
YCYe Chen
Ye Chen
Liang XuLiang Xu
Liang Xu
RLRuby Yu-Tong Lin
Ruby Yu-Tong Lin
MMMarkus Müschen
Markus Müschen
HKH. Phillip Koeffler
H. Phillip Koeffler
Transcription factors (TFs) coordinate the on-and-off states of gene expression typically in a combinatorial fashion. Studies from embryonic stem cells and other cell types have revealed that a clique of self-regulated core TFs control cell identity and cell state. These core TFs form interconnected feed-forward transcriptional loops to establish and reinforce the cell-type-specific gene-expression program; the ensemble of core TFs and their regulatory loops constitutes core transcriptional regulatory circuitry (CRC). Here, we summarize recent progress in computational reconstitution and biologic exploration of CRCs across various human malignancies, and consolidate the strategy and methodology for CRC discovery. We also discuss the genetic basis and therapeutic vulnerability of CRC, and highlight new frontiers and future efforts for the study of CRC in cancer. Knowledge of CRC in cancer is fundamental to understanding cancer-specific transcriptional addiction, and should provide important insight to both pathobiology and therapeutics.

16 March 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
CCCunjie Chang
Cunjie Chang
MRMuthukumar Rajasekaran
Muthukumar Rajasekaran
YQYiting Qiao
Yiting Qiao
HDHeng Dong
Heng Dong
YWYu Wang
Yu Wang
JCJianxiang Chen
Jianxiang Chen
Deregulation of alternative splicing is implicated as a relevant source of molecular heterogeneity in cancer. However, the targets and intrinsic mechanisms of splicing in hepatocarcinogenesis are largely unknown. Here, we report a functional impact of a Splicing Regulatory Glutamine/Lysine-Rich Protein 1 (SREK1) variant and its regulator, Serine/arginine-rich splicing factor 10 (SRSF10). HCC patients with poor prognosis express higher levels of exon 10-inclusive SREK1 (SREK1L). SREK1L can sustain BLOC1S5-TXNDC5 (B-T) expression, a targeted gene of nonsense-mediated mRNA decay through inhibiting exon-exon junction complex binding with B-T to exert its oncogenic role. B-T plays its competing endogenous RNA role by inhibiting miR-30c-5p and miR-30e-5p, and further promoting the expression of downstream oncogenic targets SRSF10 and TXNDC5. Interestingly, SRSF10 can act as a splicing regulator for SREK1L to promote hepatocarcinogenesis via the formation of a SRSF10-associated complex. In summary, we demonstrate a SRSF10/SREK1L/B-T signalling loop to accelerate the hepatocarcinogenesis.

30 April 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
Liang XuLiang Xu
Liang Xu
YCYe Chen
Ye Chen
YHYulun Huang
Yulun Huang
ESEdwin Sandanaraj
Edwin Sandanaraj
JYJohn S. Yu
John S. Yu
HKH. Phillip Koeffler
H. Phillip Koeffler
Profiling of active gene-regulatory DNA elements in brain cancer tissues illuminates disease biology and therapeutic targets.

9 February 2021 in Oncogene
Verified
Journal Article
Open access
PDF file
XKXin-Yu Ke
Xin-Yu Ke
YCYe Chen
Ye Chen
VTValarie Yu-Yan Tham
Valarie Yu-Yan Tham
RLRuby Yu-Tong Lin
Ruby Yu-Tong Lin
PDPushkar Dakle
Pushkar Dakle
HKH. Phillip Koeffler
H. Phillip Koeffler
Soft tissue sarcoma (STS) is a heterogeneous disease that arises from connective tissues. Clinical outcome of patients with advanced tumors especially de-differentiated liposarcoma and uterine leiomyosarcoma remains unsatisfactory, despite intensive treatment regimens including maximal surgical resection, radiation, and chemotherapy. MAP kinase-interacting serine/threonine-protein kinase 1 and 2 (MNK1/2) have been shown to contribute to oncogenic translation via phosphorylation of eukaryotic translation initiation factor 4E (eIF4E). However, little is known about the role of MNK1/2 and their downstream targets in STS. In this study, we show that depletion of either MNK1 or MNK2 suppresses cell viability, anchorage-independent growth, and tumorigenicity of STS cells. We also identify a compelling antiproliferative efficacy of a novel, selective MNK inhibitor ETC-168. Cellular responsiveness of STS cells to ETC-168 correlates positively with that of phosphorylated ribosomal protein S6 (RPS6). Mirroring MNK1/2 silencing, ETC-168 treatment strongly blocks eIF4E phosphorylation and represses expression of sarcoma-driving onco-proteins including E2F1, FOXM1, and WEE1. Moreover, combination of ETC-168 and MCL1 inhibitor S63845 exerts a synergistic antiproliferative activity against STS cells. In summary, our study reveals crucial roles of MNK1/2 and their downstream targets in STS tumorigenesis. Our data encourage further clinical translation of MNK inhibitors for STS treatment.

9 October 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
LMLin Ma
Lin Ma
LXLong Xie
Long Xie
YWYue Wang
Yue Wang
XGXian Guan
Xian Guan
YZYing Zhang
Ying Zhang
XHXin Han
Xin Han
As a promising cancer therapeutic target, the development of highly efficient and selective small-molecule drugs targeting CDK9 remains a significant challenge due to the similarity of its ATP-binding site to that of other CDKs. Here, we report our design, synthesis, and evaluation of CDK9 degraders with high selectivity based upon the concept of PROTAC. The representative compound dCDK9-202 demonstrates a DC50 value of 3.5 nM and Dmax > 99% in inducing rapid CDK9 degradation in the TC-71 cell line. Notably, dCDK9-202 achieves significant cell growth inhibition with an IC50 value of 8.5 nM in the TC-71 cell line and also low nanomolar IC50 values in multiple cancer cell lines originating from the lung, liver, bone, and brain. Moreover, intravenous administration of dCDK9-202 effectively inhibits TC-71 tumor growth without any signs of toxicity in mice. This promising CDK9 degrader dCDK9-202 has a high potential for advanced preclinical development in the treatment of CDK9-addicted human cancers.

9 March 2018 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
LWLicheng Wang
Licheng Wang
YTYanliang Tang
Yanliang Tang
YCYe Chen
Ye Chen
Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term poor airflow. Recently, variants in the hypoxia-inducible factor 1α ( HIF1A ) gene were found to be associated with COPD risk. This study aimed to identify whether rs10873142 polymorphism (an intronic polymorphism) in HIF1A gene was related to COPD in a Chinese population. We genotyped HIF1A gene rs10873142 polymorphism in a case-control study with 235 COPD cases and 548 controls in a Chinese Han population. Odd ratios and 95% confidence intervals were estimated using the chi-squared (χ2) test, genetic model analysis, and stratification analysis. In the genetic model analysis, we found that the TT genotype (TT vs CC: OR 1.63; 95% CI, 1.02-2.60; P = 0.042) and T allele (T VS C: OR 1.29; 95%CI, 1.02-1.60; P = 0.032) showed significantly correlation with the risk of COPD. However, in stratification analyses of Age, BMI, and FEV1/FEV, we failed to find any association between HIF1A gene rs10873142 polymorphism with COPD risk. This study supports that HIF1A gene rs10873142 polymorphism may be associated with increased risk of COPD in a Chinese Han population. To the best of our knowledge, this is the first case-control study uncovering that the HIF1A gene rs10873142 polymorphism increases the risk of COPD in a Chinese Han population.